Margret B. Einarson, Ph.D., Manager, High Throughput Screening Facility, Fox Chase Cancer Center

项目摘要 我是NCI指定的综合医院高通量筛查设施(HTSF)的经理 癌症中心福克斯·蔡斯癌症中心(FCCC)。HTSF提供筛查平台和专门的 增加实验吞吐量的仪器。特别是，HTSF允许调查人员利用 RNAi和化合物文库，以及大规模筛选所需的专门仪器 资源。自成立以来，我一直是HTSF的经理，并指导了HTSF的成立和 维护设施的方方面面。我设法购置了一套HTS设备和图书馆， 建立了所有标准操作程序(SOP)，并根据化验结果建立了工作流程 发展到为调查人员挑选统计命中。在我领导下的健康及健康发展基金成立后 管理层，在2010年NCI首次审查时，建议将其作为癌症中心的增建设施 支持助学金(CCSG)，被评为“杰出”。总体而言，我为之创造的资源的生命力 分子筛查的证据是在2007年间使用HTSF的44份出版物- 2015年。在最近的CCSG审查期内(2011-2014)，总数增加了三倍 CCSG第一次审查期内的出版物数量。在此期间，平均有超过 每年有1000个人预订设备使用。这些数据表明，资源是 已经建立并将继续发展的是可靠的，是气候变化框架公约实验室的一项关键科学资产。 随着技术和研究方向的发展，我对教师进行了调查，以确定新的技术平台 对于HTSF，我已经牵头准备了两个S10共享工具拨款两个成功的S10 允许购买Guava EasyCyte台式FACS和Luminex 100/200的应用程序，多路复用 生物标记物分析仪。收购这一新技术平台将补充可用的资源 筛查人员，但关键是允许HTSF利用患者样本和动物模型为调查人员提供服务。我的 支持和实施HTSF提供的技术的努力对于他们继续 卓越和可用性。

Project Summary I am the Manager of the High Throughput Screening Facility (HTSF) at the NCI-designated comprehensive cancer center Fox Chase Cancer Center (FCCC). The HTSF provides screening platforms and specialized instrumentation for increased experimental throughput. In particular, the HTSF allows investigators to utilize RNAi and compound libraries, and the specialized instrumentation required for large scale screening with these resources. I have been the Manager of the HTSF since its inception, and have guided the establishment and maintenance of every aspect of the facility. I managed the acquisition of a suite of HTS equipment and libraries, established all the standard operating procedures (SOPs) and created a working pipeline from assay development to statistical hit-picking for investigators. After the establishment of the HTSF under my management, on its first review by the NCI in 2010 as a proposed facility for addition to the Cancer Center Support Grant (CCSG), it was rated as “Outstanding.” Overall, the vitality of the resource I have created for molecular screening is evidenced by forty-four publications that have utilized the HTSF between the years 2007- 2015. Within the most recent CCSG review period (2011-2014), there was a three-fold increase in the total number of publications over the first CCSG review period. During this time period, there was an average of over one thousand individual reservations for equipment use per annum. These data indicate that the resources I have established and continue to develop are robust and a pivotal scientific asset for the laboratories at FCCC. As technologies and research directions evolve, I have surveyed the faculty to identify new technology platforms for the HTSF, and I have led the preparation of two S10 shared instrumentation grants two successful S10 applications allowing the purchase of the Guava EasyCyte benchtop FACS, and a Luminex 100/200, multiplexing biomarker analyzer. The acquisition of this new technology platform will complement the resources available to screeners, but crucially allow the HTSF to serve investigators utilizing patient samples and animal models. My efforts supporting and implementing the technologies provided in the HTSF is crucial to their continued excellence and availability.